Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics估計，其目前的現金和現金等價物、6,270萬美元的限制性現金和短期投資、信貸額度以及5月份承銷發行的7500萬美元收益預計將爲2026年提供現金流
Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026
Abeona Therapeutics估計，其目前的現金和現金等價物、6,270萬美元的限制性現金和短期投資、信貸額度以及5月份承銷發行的7500萬美元收益預計將爲2026年提供現金流
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。